ATE316077T1 - Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten - Google Patents
Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheitenInfo
- Publication number
- ATE316077T1 ATE316077T1 AT03009384T AT03009384T ATE316077T1 AT E316077 T1 ATE316077 T1 AT E316077T1 AT 03009384 T AT03009384 T AT 03009384T AT 03009384 T AT03009384 T AT 03009384T AT E316077 T1 ATE316077 T1 AT E316077T1
- Authority
- AT
- Austria
- Prior art keywords
- crth2
- treatment
- acid derivatives
- related diseases
- derivatives suitable
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03009384A EP1471057B1 (de) | 2003-04-25 | 2003-04-25 | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE316077T1 true ATE316077T1 (de) | 2006-02-15 |
Family
ID=32946880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03009384T ATE316077T1 (de) | 2003-04-25 | 2003-04-25 | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| AT04727274T ATE494279T1 (de) | 2003-04-25 | 2004-04-14 | Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04727274T ATE494279T1 (de) | 2003-04-25 | 2004-04-14 | Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7812160B2 (de) |
| EP (2) | EP1471057B1 (de) |
| JP (2) | JP4671955B2 (de) |
| KR (1) | KR101110491B1 (de) |
| CN (2) | CN101914065A (de) |
| AR (1) | AR043885A1 (de) |
| AT (2) | ATE316077T1 (de) |
| AU (1) | AU2004233966B2 (de) |
| BR (1) | BRPI0409733A (de) |
| CA (1) | CA2523439C (de) |
| CL (1) | CL43596B (de) |
| CY (1) | CY1111295T1 (de) |
| DE (2) | DE60303238T2 (de) |
| DK (2) | DK1471057T3 (de) |
| DO (1) | DOP2004000875A (de) |
| ES (2) | ES2257616T3 (de) |
| GT (1) | GT200400079A (de) |
| HN (1) | HN2004000129A (de) |
| IL (1) | IL171566A (de) |
| MX (1) | MXPA05011399A (de) |
| MY (1) | MY147984A (de) |
| NO (1) | NO20055588L (de) |
| NZ (1) | NZ543693A (de) |
| PE (1) | PE20050143A1 (de) |
| PL (1) | PL1633726T3 (de) |
| PT (2) | PT1471057E (de) |
| RU (1) | RU2361865C2 (de) |
| SI (1) | SI1633726T1 (de) |
| TW (1) | TWI353980B (de) |
| UY (1) | UY28286A1 (de) |
| WO (1) | WO2004096777A1 (de) |
| ZA (1) | ZA200508722B (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| ATE316077T1 (de) | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| DK2805728T3 (da) * | 2003-12-23 | 2020-04-20 | Genentech Inc | Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf |
| NZ548396A (en) | 2004-01-31 | 2010-06-25 | Actimis Pharmaceuticals Inc | Imidazo[1,2-C]pyrimidinylacetic acid derivatives |
| RU2387652C2 (ru) | 2004-03-11 | 2010-04-27 | Актелион Фармасьютиклз Лтд | Производные тетрагидропиридоиндола |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| JP5208510B2 (ja) | 2004-11-23 | 2013-06-12 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体 |
| KR101380448B1 (ko) | 2005-04-21 | 2014-04-11 | 메르크 세로노 에스. 에이. | ２，３치환된 피라진 술폰아미드 |
| EP1891075B1 (de) | 2005-05-24 | 2011-10-19 | Merck Serono SA | Tricyclische spiroderivate als crth2-modulatoren |
| PE20110118A1 (es) * | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP5155171B2 (ja) | 2005-10-06 | 2013-02-27 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2007062677A1 (en) * | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| EP2044044A2 (de) * | 2006-06-09 | 2009-04-08 | Icos Corporation | Substituierte phenylessigsäuren als dp-2-antagonisten |
| JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| UA99138C2 (ru) * | 2007-06-21 | 2012-07-25 | Актимис Фармасьютикалз, Инк. | Частичка антагониста crth2 (варианты) |
| EP2176240A1 (de) * | 2007-06-21 | 2010-04-21 | Actimis Pharmaceuticals, Inc., | Aminsalze eines crth2-antagonisten |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| KR20100061746A (ko) | 2007-09-25 | 2010-06-08 | 액티미스 파마수티컬스 인코포레이티드 | Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘 |
| PT2205569E (pt) * | 2007-09-25 | 2012-05-25 | Actimis Pharmaceuticals Inc | Alquiltiopirimidinas como antagonistas de crth2 |
| BRPI0907364A2 (pt) | 2008-02-01 | 2015-07-14 | Amira Pharmaceuticals Inc | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| WO2009108720A2 (en) | 2008-02-25 | 2009-09-03 | Amira Pharmaceuticals, Inc. | Antagonists of prostaglandin d2 receptors |
| WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| AU2009266793B2 (en) | 2008-07-03 | 2012-12-20 | Brickell Biotech, Inc. | Antagonists of prostaglandin D2 receptors |
| WO2010027448A1 (en) * | 2008-09-02 | 2010-03-11 | Actimis Pharmaceuticals Inc. | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| CA2747795A1 (en) * | 2008-12-25 | 2010-07-01 | Taisho Pharmaceutical Co., Ltd. | Isoquinoline derivative |
| EP2393492A1 (de) * | 2009-02-09 | 2011-12-14 | Boehringer Ingelheim International GmbH | Neue pharmazeutische zusammensetzungen zur behandlung von atemwegs- und gastrointestinalen erkrankungen |
| JP2012517454A (ja) | 2009-02-12 | 2012-08-02 | メルク セローノ ソシエテ アノニム | フェノキシ酢酸誘導体 |
| WO2010094643A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| EP2461809A4 (de) | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | Pharmazeutische zusammensetzungen für die augen aus dp2-rezeptor-antagonisten |
| EP2462110A4 (de) | 2009-08-05 | 2013-04-03 | Panmira Pharmaceuticals Llc | Dp2-antagonist und seine verwendung |
| GB0913636D0 (en) * | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| MX2012006003A (es) * | 2009-11-24 | 2012-06-19 | Boehringer Ingelheim Int | Procedimiento para preparar un polimorfo de la sal de colina de [4,6-bis(dimetilamino)-2-(4-{[4-(trifluorometil)-benzoil]amino}be ncil)pirimidin-5-ilo]. |
| AU2011203649A1 (en) | 2010-01-06 | 2012-06-14 | Brickell Biotech, Inc. | DP2 antagonist and uses thereof |
| MY160036A (en) | 2010-01-27 | 2017-02-15 | Boehringer Ingelheim Int | Pyrazole compounds as crth2 antagonists |
| KR20130087399A (ko) | 2010-06-23 | 2013-08-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 이소퀴놀린 유도체 |
| JP5800898B2 (ja) | 2010-07-05 | 2015-10-28 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| EP2598145A1 (de) * | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmazeutische zusammensetzungen zur behandlung von atemwegs- und entzündungserkrankungen |
| EP2598143A1 (de) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmazeutische zusammensetzungen zur behandlung von atemwegs- und entzündungskrankheiten |
| KR102090990B1 (ko) | 2010-10-20 | 2020-03-19 | 에스더블유아이엠씨 엘엘씨 | 머플러 등급의 스테인리스 강을 포함하는 넓은 범위의 코팅 및 비코팅 기재에의 접착성이 향상된 수계 코팅 시스템 |
| NZ610315A (en) | 2010-11-15 | 2015-08-28 | Univ Leuven Kath | Antiviral condensed heterocyclic compounds |
| EP2457900A1 (de) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten |
| TWI527809B (zh) | 2011-01-24 | 2016-04-01 | 百靈佳殷格翰國際股份有限公司 | 作為ｃｒｔｈ２拮抗劑之吡唑化合物 |
| US9206164B2 (en) | 2011-03-25 | 2015-12-08 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| SI2709988T1 (sl) * | 2011-05-16 | 2017-11-30 | Actimis Pharmaceuticals, Inc. | Postopek za pripravo (4,6-bis-dimetilamino-2- (4- (4- trifluorometilbenzoil-amino)benzil) primidin-5-il) ocetne kisline |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| RU2014129613A (ru) | 2011-12-21 | 2016-02-10 | Актелион Фармасьютиклз Лтд | Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2 |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| US20140148470A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrimidine compounds for treating hairloss |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| US6326368B1 (en) * | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| AU723234B2 (en) * | 1996-09-06 | 2000-08-24 | Nippon Kayaku Kabushiki Kaisha | Novel acetamide derivatives and protease inhibitors |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| RU2270194C2 (ru) * | 2000-05-22 | 2006-02-20 | Лео Фарма А/С | Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1413306A1 (de) * | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydrochinolin-Derivate als CRTH2 Antagonisten |
| AU2003297398B2 (en) | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
| ATE316077T1 (de) | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| EP2176240A1 (de) | 2007-06-21 | 2010-04-21 | Actimis Pharmaceuticals, Inc., | Aminsalze eines crth2-antagonisten |
| UA99138C2 (ru) | 2007-06-21 | 2012-07-25 | Актимис Фармасьютикалз, Инк. | Частичка антагониста crth2 (варианты) |
-
2003
- 2003-04-25 AT AT03009384T patent/ATE316077T1/de active
- 2003-04-25 DK DK03009384T patent/DK1471057T3/da active
- 2003-04-25 ES ES03009384T patent/ES2257616T3/es not_active Expired - Lifetime
- 2003-04-25 EP EP03009384A patent/EP1471057B1/de not_active Expired - Lifetime
- 2003-04-25 DE DE60303238T patent/DE60303238T2/de not_active Expired - Lifetime
- 2003-04-25 PT PT03009384T patent/PT1471057E/pt unknown
-
2004
- 2004-04-01 DO DO2004000875A patent/DOP2004000875A/es unknown
- 2004-04-14 RU RU2005136655/04A patent/RU2361865C2/ru not_active IP Right Cessation
- 2004-04-14 EP EP04727274A patent/EP1633726B1/de not_active Expired - Lifetime
- 2004-04-14 PL PL04727274T patent/PL1633726T3/pl unknown
- 2004-04-14 AT AT04727274T patent/ATE494279T1/de active
- 2004-04-14 ZA ZA200508722A patent/ZA200508722B/en unknown
- 2004-04-14 JP JP2006505114A patent/JP4671955B2/ja not_active Expired - Fee Related
- 2004-04-14 MX MXPA05011399A patent/MXPA05011399A/es active IP Right Grant
- 2004-04-14 BR BRPI0409733-5A patent/BRPI0409733A/pt not_active IP Right Cessation
- 2004-04-14 KR KR1020057020304A patent/KR101110491B1/ko not_active Expired - Fee Related
- 2004-04-14 ES ES04727274T patent/ES2358424T3/es not_active Expired - Lifetime
- 2004-04-14 DK DK04727274.5T patent/DK1633726T3/da active
- 2004-04-14 WO PCT/EP2004/003910 patent/WO2004096777A1/en not_active Ceased
- 2004-04-14 US US10/554,668 patent/US7812160B2/en not_active Expired - Fee Related
- 2004-04-14 CN CN2010101716294A patent/CN101914065A/zh active Pending
- 2004-04-14 CA CA2523439A patent/CA2523439C/en not_active Expired - Fee Related
- 2004-04-14 PT PT04727274T patent/PT1633726E/pt unknown
- 2004-04-14 SI SI200431585T patent/SI1633726T1/sl unknown
- 2004-04-14 DE DE602004030907T patent/DE602004030907D1/de not_active Expired - Lifetime
- 2004-04-14 CN CN2004800173378A patent/CN1809539B/zh not_active Expired - Fee Related
- 2004-04-14 NZ NZ543693A patent/NZ543693A/en not_active IP Right Cessation
- 2004-04-14 AU AU2004233966A patent/AU2004233966B2/en not_active Ceased
- 2004-04-19 AR ARP040101311A patent/AR043885A1/es not_active Application Discontinuation
- 2004-04-21 GT GT200400079A patent/GT200400079A/es unknown
- 2004-04-21 HN HN2004000129A patent/HN2004000129A/es unknown
- 2004-04-22 MY MYPI20041479A patent/MY147984A/en unknown
- 2004-04-23 PE PE2004000402A patent/PE20050143A1/es not_active Application Discontinuation
- 2004-04-23 UY UY28286A patent/UY28286A1/es not_active Application Discontinuation
- 2004-04-23 CL CL200400874A patent/CL43596B/es active
- 2004-04-23 TW TW093111323A patent/TWI353980B/zh not_active IP Right Cessation
-
2005
- 2005-10-26 IL IL171566A patent/IL171566A/en not_active IP Right Cessation
- 2005-11-25 NO NO20055588A patent/NO20055588L/no not_active Application Discontinuation
-
2010
- 2010-08-25 US US12/868,663 patent/US7960393B2/en not_active Expired - Fee Related
- 2010-11-08 JP JP2010249273A patent/JP5161290B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-03 CY CY20111100113T patent/CY1111295T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE316077T1 (de) | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten | |
| ATE390925T1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
| DE602005023172D1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
| DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
| DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
| ATE369333T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| ATE390407T1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| ATE512663T1 (de) | Kombination zur behandlung von erkrankungen mit zellproliferation | |
| DE60325209D1 (de) | Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen | |
| DE502005007427D1 (de) | 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| ATE375977T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| ATE527241T1 (de) | Pyridiazinonderivate zur behandlung von tumoren | |
| ATE540949T1 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| DE602004003952D1 (de) | Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
| ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1471057 Country of ref document: EP |